Fluid Biopsy Market to reach $54.3 billion by 2030; The increase in prevalence of cancer worldwide, non-invasive nature of procedures which reduce the risk of complications associated with surgical biopsies, growing cancer awareness programs by gover

The Fluid Biopsy Market size is estimated to reach $54.3 billion by 2030, growing at a CAGR of 19.6% during the forecast period 2024-2030, according to a recent report published by IndustryARC, titled, “ Fluid Biopsy Market  -  By Product (Test & Services, Kits & Consumables and Instruments), By Cancer (Lung Cancer, Breast Cancer, Colorectal Cancer, Bone Cancer, Cervical Cancer, Adrenal Cancer, Intestinal Cancer, Kidney Cancer and Others), By Circulating Biomarker (Circulating Tumor Cells (CTCs), Circulating Tumor DNA (ctDNA), Cell-Free DNA (cfDNA), Exosomes, Extracellular Vesicles and Others), By Technology (NGS, PCR, FISH and Other), By Sample Type (Blood, Urine, Saliva, CerebroSpinal Fluid and Others), By Application (Diagnosis & Screening, Therapy Selection, Treatment Monitoring, Recurrence Monitoring and Others), By Geography - Global Opportunity Analysis & Industry Forecast, 2024-2030”. 

The main driver of the Fluid Biopsy market is the rising prevalence of cancer cases which drives the need for fluid biopsy procedures to diagnose in a better way. Additionally, growing cancer awareness programs by governments and investments in cancer hospitals and cancer research are also fueling the growth of the Fluid Biopsy industry during the forecast period. 

North America accounted for the largest share of 37% of the Fluid Biopsy Market in 2023. Investments in cancer research and diagnosis are fueling the fluid biopsy market growth in this region. For instance, The President’s FY 2024 Budget makes strategic investments in the Cancer Moonshot as part of the President’s Unity Agenda to deliver new ways to prevent, detect, and treat cancer. As a part of this government provided $1.7 billion at the Department of Health and Human Services (HHS) to support dedicated Cancer Moonshot activities at the National Cancer Institute (NCI), Centers for Disease Control and Prevention (CDC), Food and Drug Administration (FDA), and Health Resources and Services Administration (HRSA), and Indian Health Service (IHS). Additionally, sanctioned $360 million at the Department of Veterans Affairs (VA) for research to expand knowledge on the biological understanding, diagnosis, prognosis, treatment, and prevention of cancer, as well as to support healthcare utilization, delivery of care to cancer patients, and the delivery, efficacy, and effectiveness of therapies. Such investments are providing a way to adoption of advanced procedures like fluid biopsy for effective diagnosis. 

Developing countries are experiencing a period of significant healthcare infrastructure growth. Ever since the pandemic, investments are pouring in from governments and private investors into building new hospitals and upgrading existing facilities. In September 2023, the White House announced a $240 million investment to fight cancer, the money will go to researchers working on cancer prevention, detection, treatment and survival projects. In July 2024, the Australian government invested approximately $720 million into developing the 150-bed Queensland Cancer Centre which is slated to open in 2028. The establishment of the Cancer Centre aligns with the government’s Queensland Cancer Plan, a 10-year initiative with over $1.1 billion in investments. Such investments are expected to boost the market. 

Growing cancer awareness programs by governments is a significant driver in the Fluid Biopsy market. For instance, in a significant move to combat cancer, In June 2024, the Andhra Pradesh State government launched a comprehensive cancer screening programme (CCSP) in collaboration with Homi Bhabha Cancer Hospital and Research Institute, Visakhapatnam and the World Health Organisation (WHO). This initiative targets individuals aged 30 and above, aiming to screen for breast, oral cavity (dental), and cervical cancers. This initiative aims to improve the early detection and management of cancer cases across the State by leveraging the expertise of medical colleges and secondary care hospitals. Such awareness programs are expected to boost the market.  

Key companies profiled in the Fluid Biopsy Market are Guardant Health, Illumina, Thermo Fisher Scientif, QIAGEN, Myriad genetics, F. Hoffmann-La Roche AG, Angle plc, Ocimmune, Sysmex Corporation, Bio-Rad Laboratories and Others.  

Breast Biopsy Market - Breast Biopsy Devices Market Size is valued at $3.4 Billion by 2030, and is anticipated to grow at a CAGR of 5.1% during the forecast period 2024 -2030. The breast biopsy device market is experiencing significant growth, driven by advancements in medical technology, rising incidence of breast cancer, and increasing awareness about early detection.  

Prostate Biopsy Market - Prostate Biopsy Market size is estimated to reach $6,650 million by 2026, after growing at a CAGR of 5% during the forecast period 2021-2026. Prostate biopsy is used for the treatment of prostate cancer which is ideal to collect sample tissue from prostate to identify cancer.  

Cancer Diagnostics Market - The Cancer Diagnostics Market size is estimated to reach $241.7 billion by 2027, growing at a CAGR of 6.3% during the forecast period 2022-2027. Cancer Diagnostics includes tests and processes to ratify the existence of ailment and recognize the precise tumor type, location, extent and phase.